207 related articles for article (PubMed ID: 32306401)
1. A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s.
Guaraldi F; Zoli M; Righi A; Gibertoni D; Marino Picciola V; Faustini-Fustini M; Morandi L; Bacci A; Pasquini E; Mazzatenta D; Asioli S
Clin Endocrinol (Oxf); 2020 Jul; 93(1):36-43. PubMed ID: 32306401
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre.
Asioli S; Righi A; Iommi M; Baldovini C; Ambrosi F; Guaraldi F; Zoli M; Mazzatenta D; Faustini-Fustini M; Rucci P; Giannini C; Foschini MP
Eur J Endocrinol; 2019 Feb; 180(2):127-134. PubMed ID: 30481158
[TBL] [Abstract][Full Text] [Related]
3. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification.
Raverot G; Dantony E; Beauvy J; Vasiljevic A; Mikolasek S; Borson-Chazot F; Jouanneau E; Roy P; Trouillas J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3368-3374. PubMed ID: 28651368
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.
Cossu G; La Rosa S; Brouland JP; Pitteloud N; Harel E; Santoni F; Brunner M; Daniel RT; Messerer M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760441
[TBL] [Abstract][Full Text] [Related]
5. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J; Roy P; Sturm N; Dantony E; Cortet-Rudelli C; Viennet G; Bonneville JF; Assaker R; Auger C; Brue T; Cornelius A; Dufour H; Jouanneau E; François P; Galland F; Mougel F; Chapuis F; Villeneuve L; Maurage CA; Figarella-Branger D; Raverot G; ; Barlier A; Bernier M; Bonnet F; Borson-Chazot F; Brassier G; Caulet-Maugendre S; Chabre O; Chanson P; Cottier JF; Delemer B; Delgrange E; Di Tommaso L; Eimer S; Gaillard S; Jan M; Girard JJ; Lapras V; Loiseau H; Passagia JG; Patey M; Penfornis A; Poirier JY; Perrin G; Tabarin A
Acta Neuropathol; 2013 Jul; 126(1):123-35. PubMed ID: 23400299
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
7. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
9. MRI and Trouillas' grading system of pituitary tumors: the usefulness of T2 signal intensity volumetric values.
Calandrelli R; Pilato F; D'Apolito G; Schiavetto S; Gessi M; D'Alessandris QG; Lauretti L; Gaudino S
Neuroradiology; 2023 Nov; 65(11):1567-1578. PubMed ID: 37233819
[TBL] [Abstract][Full Text] [Related]
10. Real-life clinical impact of a five-tiered classification of pituitary tumors.
Sahakian N; Appay R; Resseguier N; Graillon T; Piazzola C; Laure C; Figarella-Branger D; Régis J; Castinetti F; Brue T; Dufour H; Cuny T
Eur J Endocrinol; 2022 Dec; 187(6):893-904. PubMed ID: 36315463
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
13. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
14. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract][Full Text] [Related]
15. Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype.
Taguchi A; Kinoshita Y; Amatya VJ; Onishi S; Go Y; Tominaga A; Takeshima Y; Yamasaki F; Horie N
Neurosurg Rev; 2023 Nov; 46(1):317. PubMed ID: 38030890
[TBL] [Abstract][Full Text] [Related]
16. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C; Baussart B; Assié G; Raverot G; Roncaroli F
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37068095
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
Lv L; Yin S; Zhou P; Hu Y; Chen C; Ma W; Jiang Y; Wang Z; Jiang S
World Neurosurg; 2018 Oct; 118():e428-e435. PubMed ID: 29981466
[TBL] [Abstract][Full Text] [Related]
18. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
19. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
20. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
